Ankylosing Spondylitis: Symptoms and Treatment
Typical Symptoms
Ankylosing spondylitis presents with inflammatory back pain characterized by nocturnal awakening, prolonged morning stiffness (lasting >30 minutes), improvement with exercise but not rest, and diurnal variation with symptoms worse in early morning 1.
Key clinical features include:
- Axial manifestations: Chronic lower back pain and stiffness affecting the sacroiliac joints and spine, potentially progressing to spinal fusion and postural deformity 2
- Peripheral manifestations: Enthesitis (inflammation at tendon/ligament insertion sites), peripheral arthritis (particularly oligoarthritis), and dactylitis 3
- Extra-articular manifestations: Acute anterior uveitis (eye inflammation), inflammatory bowel disease, psoriasis, and aortitis 2
- Systemic symptoms: Fatigue and functional impairment comparable to rheumatoid arthritis 1
The disease typically manifests in males during their third decade, though women are increasingly recognized 2.
Treatment Algorithm
First-Line Treatment: NSAIDs
For patients with active ankylosing spondylitis, NSAIDs are strongly recommended as initial pharmacological management 3, 4. No particular NSAID is preferred over another 4.
- For active disease: Continuous NSAID therapy is conditionally recommended over on-demand use to control symptoms 3, 4
- For stable disease: On-demand NSAID use is strongly recommended over continuous treatment 3
- NSAID failure definition: Consider treatment failure after 1 month of continuous use (at least two different NSAIDs for 15 days each) 3
Important caveat: Continuous NSAIDs should be used for symptom control only, not to prevent structural progression, as evidence for radiographic benefit is inconsistent 3. Use selective COX-2 inhibitors when available in patients at high risk for adverse events 3.
Second-Line Treatment: Biologic DMARDs
For patients with active disease despite NSAIDs (ASDAS ≥2.1) who have failed ≥2 NSAIDs AND demonstrate either elevated CRP, MRI inflammation of sacroiliac joints, or radiographic sacroiliitis, initiate biologic therapy with either TNF inhibitors or IL-17 inhibitors 5.
Biologic Selection Strategy:
Current practice is to start with a TNF inhibitor or IL-17 inhibitor as first-line biologic therapy 5. The choice should be guided by extra-articular manifestations:
- TNF monoclonal antibodies (infliximab, adalimumab, certolizumab, golimumab): Preferred for patients with recurrent acute anterior uveitis or inflammatory bowel disease 5
- IL-17 inhibitors (secukinumab, ixekizumab): Preferred for patients with significant psoriasis 5
- TNF inhibitors are conditionally recommended over IL-17 inhibitors when extra-articular features are absent 4
Available TNF inhibitors include infliximab, etanercept, adalimumab, certolizumab, golimumab, and their biosimilars, with no particular agent preferred 4.
Third-Line: Biologic Switching
If the first biologic fails, the approach depends on the type of failure:
- Primary non-response to TNFi (no improvement within 3-6 months): Switch to secukinumab or ixekizumab conditionally recommended over switching to another TNFi 4
- Secondary non-response to TNFi (loss of response after initial benefit): Switch to a different TNFi conditionally recommended over non-TNFi biologics 4
- Strongly recommend against switching to a biosimilar of the same TNFi that failed 4
Role of Conventional Synthetic DMARDs
Sulfasalazine or methotrexate should be considered ONLY in patients with prominent peripheral arthritis or when TNF inhibitors are not available 4. These agents are conditionally recommended but have very low to moderate evidence for pure axial disease 4.
Tofacitinib (JAK inhibitor) is conditionally recommended but ranks below TNFi and IL-17 inhibitors in the treatment hierarchy 4.
Treatments to Avoid
Long-term systemic glucocorticoids are strongly recommended against in axial spondyloarthritis 3. Local glucocorticoid injections may be conditionally used for isolated active sacroiliitis, enthesitis, or monoarthritis/oligoarthritis despite NSAIDs 3.
Non-Pharmacological Management
Physical therapy with consistent exercise, stretching, and posture maintenance is essential 2. Patients should be managed with experts in physical medicine and rehabilitation 3.
Monitoring Strategy
Monitor disease activity at regular intervals using ASDAS (Ankylosing Spondylitis Disease Activity Score) and/or SASDAS, along with CRP and/or ESR 3. The treatment target is remission or sustained low disease activity 3.
Routine MRI or radiographic studies for follow-up are strongly recommended against 3—imaging should be reserved for diagnostic purposes or specific clinical questions, not routine monitoring.
Stable Disease Management
For patients achieving stable disease on biologics, continue the biologic alone and stop NSAIDs 4. Tapering (rather than immediate discontinuation) can be considered in patients with sustained remission 5.
Critical Pitfalls
- Do not delay biologic therapy in patients meeting criteria—early intervention improves outcomes
- Evaluate for extra-articular manifestations before selecting biologics, as this significantly impacts drug choice
- If treatment fails, re-evaluate the diagnosis and assess for comorbidities before switching agents 5
- Bone metabolism evaluation and fracture risk assessment with validated methods is strongly recommended given increased osteoporosis risk 3